Back

Continuation of HER2-targeted therapy using a permissive cardiotoxicity approach in patients with cancer therapy-related cardiac dysfunction

19 June 2026 (08:30 - 17:30)
Organised by: Logo
Congress Presentation Part of: Poster session (1) Diagnosis and Management of Cardiovascular Disease in Patients with Cancer Delegates Premium Access ESC Cardio-Oncology 2026 Council of Cardio-Oncology

About the speaker

Photo
Doctor Amaya Abeydeera

Victorian Heart Hospital, Clayton (Australia)

45 More presentations in this session

Presentation thumbnail
Exploring lipoprotein(a) and incident heart failure in cancer patients with anthracycline-associated neoplasms
Mrs A. Stephanus (Brasilia, BR)
Abstract Slides
Presentation thumbnail
ICARE-TNBC : Immune checkpoint-associated cardiotoxicity risk evaluation in early-stage triple-negative breast cancer
Miss L. Dib (Paris, FR)
Abstract
Presentation thumbnail
Incidence and risk profile of venous thromboembolic events in patients undergoing immune checkpoint inhibitor therapy
Doctor Z. Sandor (Budapest, HU)
Abstract Slides
Presentation thumbnail
Pericoronary fat attenuation on coronary ct identifies persistent vascular inflammation after chest radiotherapy in cancer survivors
Doctor T. De Silva (Kings Lynn, GB)
Abstract Slides
Presentation thumbnail
Optimizing troponin T screening for immune checkpoint inhibitor-associated myocarditis
Mr T. Uyl (Rotterdam, NL)
Abstract Slides

Access the full session

Session thumbnail
Poster session (1)

The Event

Event poster

ESC Cardio-Oncology 2026

19 June 2026 08:30 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources